Pharmacological action and clinical aspects of salmeterol

DOI Web Site Web Site PubMed 44 References
  • OGURI Kojiro
    Scientific Support Section, Respiratory Marketing Department, Franchise Products Division, GlaxoSmithKline K.K.

Bibliographic Information

Other Title
  • 長時間作動型吸入β<sub>2</sub>刺激薬キシナホ酸サルメテロール（セレベント<sup>®</sup>）の薬理作用および臨床効果
  • 新薬紹介総説 長時間作動型吸入β2刺激薬キシナホ酸サルメテロール(セレベント)の薬理作用および臨床効果
  • シンヤク ショウカイ ソウセツ チョウジカン サドウガタ キュウニュウ ベータ 2 シゲキヤク キシナホサン サルメテロール セレベント ノ ヤクリ サヨウ オヨビ リンショウ コウカ

Search this article

Description

Previous systemic β2 agonists such as procatrol tablets and tulobuterol patch were developed in Japan to address nocturnal symptoms and maintenance of lung function in asthmatic patients. Salmeterol, a potent and highly selective in β2 adrenocepter agonist with a duration of action greater than 12 h, was developed to provide long duration of bronchodilation with binding to a non-active site in the β2-adrenocepter. Salmeterol is administrated via dry power inhalation and clinical studies have showed it has a good efficacy and a good safety profile, similar to inhaled steroids. Indeed, many clinical studies showed that salmeterol demonstrated better efficacy than long-acting β2-agonist oral bronchodilators, theophyllines, and leukotriene-receptor antagonists in asthmatic patients and anticholinergic agents and theophyllines in COPD patients. Salmeterol will provide clinical benefits for Japanese asthma and COPD patients.<br>

Journal

References(44)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top